The Latest Breaking News from PBMs

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

A deal announced this week on a series of drug pricing bills could be a sign of progress an issue that has bedeviled both parties.

Prosecutors could end up with a trove of patient-level data regarding highly personal drugs like Viagra, abortion pills, and more.

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

Almost four years after becoming the first state to cap insulin copayments, Colorado may limit what consumers pay for epinephrine autoinjectors, also known as EpiPens, which treat serious allergic reactions.

Colorado’s proposed legislation to cap EpiPen copays is part of a nationwide effort against skyrocketing drug prices.

The billionaire entrepreneur is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.

WASHINGTON — Factions of the health care system and members of Congress are turning their fire on an oft-maligned part of the drug pricing system — the middlemen who negotiate discounts with drug companies on behalf of health plans.

PBMs argue that the rebates they collect from drug companies in exchange for coverage by a health plan are used to lower premiums.

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

U.S. Sen. Raphael Warnock just introduced a bill that would cap Americans’ out-of-pocket spending on insulin at $35 a month. The legislation would be a godsend to patients battling diabetes. Many of them currently face hundreds of dollars in monthly out-of-pocket costs — an unaffordable burden for many low- and…